Thermo Fisher Scientific ZFYVE26 Polyclonal Antibody

Applications and Tested Dilution

Product Specifications

Product Specific Information

• Suggested positive control: rat heart tissue lysate
• PA5-20685 can be used with blocking peptide PEP-0801.

Target Information

Hereditary spastic paraplegias (HSPs) are genetically and phenotypically heterogeneous disorders. Spastic paraplegia with thinning of the corpus callosum (ARHSP-TCC) is a relatively frequent form of complicated hereditary spastic paraplegia characterized by mental retardation and muscle stiffness at onset, followed by slowly progressive paraparesis and cognitive deterioration.
SPG15 is the second gene known to be responsible for ARHSP-TCC in the Italian population. Mutations in this gene are associated with autosomal recessive spastic paraplegia-15.

SPG15 encodes a protein containing a FYVE zinc finger binding domain, which is thought to target these proteins to membrane lipids through interaction with phospholipids. SPG15 mRNA is widely distributed in human tissues and rat embryos, suggesting a possible role during embryonic development. SPG15 co-localizes partially with endoplasmic reticulum and endosome markers, indicating a role in intracellular trafficking. Multiple isoforms of SPG15 are known to exist.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.